FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1970681680> ?p ?o ?g. }

• W1970681680 endingPage "2539" @default.
• W1970681680 startingPage "2529" @default.
• W1970681680 abstract "Background. In an attempt to learn how best to administer granulocyte-macrophage colony-stimulating factor (GMCSF), the authors performed a Phase I study of this agent. They were interested in the influences of dose, schedule, and route of administration on the effects of GMCSF in patients receiving standardized 1-day regimens of cyclophosphamide (CYCLO) and carboplatin (CBDCA). Methods. Between June 1988 and March 1991,57 patients with advanced cancer received GMCSF in association with CYCLO 1 g/m2 plus CBDCA 225-700 mg/mz. After the first dose escalation to 300 mg/m2 of CBDCA, patients who had previously received chemotherapy or radiation therapy were excluded. GMCSF was administered in three different doses, five different schedules, and by two different routes. Altogether, 17 different treatment groups were observed. In addition, 24-hour GMCSF serum concentration curves were charted in four patients. Results. Using four sequential groups of three patients each who had received myelosuppressive treatment, treatment with CYCLO 1 g/m2 and CBDCA 225 mg/m2, the apparent superiority of daily subcutaneous injection over 30-minute daily IV infusion of GMCSF was demonstrated graphically. Subsequently, the authors observed apparent enhancement of GMCSF effects beyond those produced by the initially selected 20-day basic 10 μg/kg daily SC regimen beginning 2 days after chemotherapy. When administered SC every 12 hours for 14 days beginning the day after chemotherapy, GMCSF appeared to ameliorate the severity of both leukopenia and thrombocytopenia. These effects permitted escalation of the CBDCA dose to 700 mg/m2 (with 1 g/m2 of CYCLO) before cytotoxic tolerance limits were reached. Graphic small group comparisons suggest that GMCSF given SC in doses of 5 pg/kg twice daily may produce comparable leukocyte and platelet support after chemotherapy with lower toxicity than occurs from higher doses. Prechemotherapy priming with GMCSF twice daily for an additional 4 days (days −6 to −3) seems to ameliorate post-chemotherapy cytopenias further but at the cose of some increased risk of GMCSF toxicity. Although most of the toxic effects of moderate-dose GMCSF are controlled by antihistamines and ibuprofen, oral glucocorticoids (e.g., prednisone, 10 mg twice daily during the second week of GMCSF administration) may be required in patients with serositis, pulmonary infiltrates, or severe skin eruptions. Conclusions. Our observations suggest that GMCSF should be administered SC in doses of approximately 5 μg/kg every 12 hours for 10-14 days beginning the day after chemotherapy. Prechemotherapy priming with these same doses for four additional days (days −6 to −3) may additionally ameliorate postchemotherapy leukopenia and thrombocytopenia, but with increased risk of toxicity." @default.
• W1970681680 created "2016-06-24" @default.
• W1970681680 creator A5005798440 @default.
• W1970681680 creator A5016095265 @default.
• W1970681680 creator A5028321867 @default.
• W1970681680 creator A5029941846 @default.
• W1970681680 creator A5035607232 @default.
• W1970681680 creator A5057155689 @default.
• W1970681680 creator A5070117777 @default.
• W1970681680 creator A5071305709 @default.
• W1970681680 date "1992-11-15" @default.
• W1970681680 modified "2023-09-23" @default.
• W1970681680 title "Granulocyte-macrophage colony-stimulating factor: Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin" @default.
• W1970681680 cites W1813117450 @default.
• W1970681680 cites W1964368530 @default.
• W1970681680 cites W1965273796 @default.
• W1970681680 cites W1969194020 @default.
• W1970681680 cites W1973034088 @default.
• W1970681680 cites W1980439854 @default.
• W1970681680 cites W1988136679 @default.
• W1970681680 cites W1990376418 @default.
• W1970681680 cites W2053807737 @default.
• W1970681680 cites W2068382284 @default.
• W1970681680 cites W2071595697 @default.
• W1970681680 cites W2078325972 @default.
• W1970681680 cites W2103937418 @default.
• W1970681680 cites W2149894706 @default.
• W1970681680 cites W2241219494 @default.
• W1970681680 cites W2243036876 @default.
• W1970681680 cites W2249202800 @default.
• W1970681680 cites W2313477330 @default.
• W1970681680 cites W2317007280 @default.
• W1970681680 cites W2318040193 @default.
• W1970681680 cites W2337660074 @default.
• W1970681680 cites W2404846580 @default.
• W1970681680 cites W2408945085 @default.
• W1970681680 cites W2593892363 @default.
• W1970681680 cites W4248364932 @default.
• W1970681680 doi "https://doi.org/10.1002/1097-0142(19921115)70:10<2529::aid-cncr2820701023>3.0.co;2-h" @default.
• W1970681680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1423182" @default.
• W1970681680 hasPublicationYear "1992" @default.
• W1970681680 type Work @default.
• W1970681680 sameAs 1970681680 @default.
• W1970681680 citedByCount "32" @default.
• W1970681680 countsByYear W19706816802020 @default.
• W1970681680 crossrefType "journal-article" @default.
• W1970681680 hasAuthorship W1970681680A5005798440 @default.
• W1970681680 hasAuthorship W1970681680A5016095265 @default.
• W1970681680 hasAuthorship W1970681680A5028321867 @default.
• W1970681680 hasAuthorship W1970681680A5029941846 @default.
• W1970681680 hasAuthorship W1970681680A5035607232 @default.
• W1970681680 hasAuthorship W1970681680A5057155689 @default.
• W1970681680 hasAuthorship W1970681680A5070117777 @default.
• W1970681680 hasAuthorship W1970681680A5071305709 @default.
• W1970681680 hasBestOaLocation W19706816801 @default.
• W1970681680 hasConcept C126322002 @default.
• W1970681680 hasConcept C141071460 @default.
• W1970681680 hasConcept C2776093070 @default.
• W1970681680 hasConcept C2776694085 @default.
• W1970681680 hasConcept C2776755627 @default.
• W1970681680 hasConcept C2777478134 @default.
• W1970681680 hasConcept C2777767877 @default.
• W1970681680 hasConcept C2777983669 @default.
• W1970681680 hasConcept C2778239845 @default.
• W1970681680 hasConcept C2778690821 @default.
• W1970681680 hasConcept C2780873365 @default.
• W1970681680 hasConcept C2781413609 @default.
• W1970681680 hasConcept C2781451048 @default.
• W1970681680 hasConcept C71924100 @default.
• W1970681680 hasConcept C98274493 @default.
• W1970681680 hasConceptScore W1970681680C126322002 @default.
• W1970681680 hasConceptScore W1970681680C141071460 @default.
• W1970681680 hasConceptScore W1970681680C2776093070 @default.
• W1970681680 hasConceptScore W1970681680C2776694085 @default.
• W1970681680 hasConceptScore W1970681680C2776755627 @default.
• W1970681680 hasConceptScore W1970681680C2777478134 @default.
• W1970681680 hasConceptScore W1970681680C2777767877 @default.
• W1970681680 hasConceptScore W1970681680C2777983669 @default.
• W1970681680 hasConceptScore W1970681680C2778239845 @default.
• W1970681680 hasConceptScore W1970681680C2778690821 @default.
• W1970681680 hasConceptScore W1970681680C2780873365 @default.
• W1970681680 hasConceptScore W1970681680C2781413609 @default.
• W1970681680 hasConceptScore W1970681680C2781451048 @default.
• W1970681680 hasConceptScore W1970681680C71924100 @default.
• W1970681680 hasConceptScore W1970681680C98274493 @default.
• W1970681680 hasIssue "10" @default.
• W1970681680 hasLocation W19706816801 @default.
• W1970681680 hasLocation W19706816802 @default.
• W1970681680 hasOpenAccess W1970681680 @default.
• W1970681680 hasPrimaryLocation W19706816801 @default.
• W1970681680 hasRelatedWork W1970200901 @default.
• W1970681680 hasRelatedWork W1970681680 @default.
• W1970681680 hasRelatedWork W1975045405 @default.
• W1970681680 hasRelatedWork W2041579112 @default.
• W1970681680 hasRelatedWork W2048702284 @default.
• W1970681680 hasRelatedWork W2080434356 @default.
• W1970681680 hasRelatedWork W2094950931 @default.
• W1970681680 hasRelatedWork W2355621512 @default.

• next